Phase I trial of fixed dose rate infusion (FDRI) gemcitabine (GEM) with gefitinib in patients with advanced pancreatic carcinoma.

被引：0
|
作者：
Carneiro, B [1 ]
Brand, R [1 ]
Fine, E [1 ]
Knop, R [1 ]
Khandekar, J [1 ]
Uhlig, W [1 ]
Locker, GY [1 ]
机构：
[1] Evanston NW Healthcare, Evanston, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：337S / 337S
页数：1
相关论文
共 50 条
  • [41] Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas
    Feliu, J.
    Saenz, J. Garcia
    Jaraiz, A. Rodriguez
    Castanon, C.
    Cruz, M.
    Fonseca, E.
    Lomas, M.
    Castro, J.
    Jara, C.
    Casado, E.
    Leon, A.
    Baron, M. Gonzalez
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 419 - 426
  • [42] Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas
    Feliu, J
    Mel, R
    Borrega, P
    Gómez, LL
    Escudero, P
    Dorta, J
    Castro, J
    Vázquez-Estévez, SE
    Bolaños, M
    Espinosa, E
    Barón, MG
    ANNALS OF ONCOLOGY, 2002, 13 (11) : 1756 - 1762
  • [43] Phase I study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy in gemcitabine-refractory pancreatic cancer patients.
    Morizane, C.
    Okusaka, T.
    Furuse, J.
    Ishii, H.
    Ueno, H.
    Ikeda, M.
    Ogura, T.
    Nakachi, K.
    Suzuki, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 272 - 273
  • [44] GEMCITABINE (G) FIXED RATE DOSE INFUSION (FDR) PLUS ERLOTINIB (E) IN PATIENTS WITH ADVANCED PANCREATIC CANCER (APC)
    Munoz, A.
    Azkona, E.
    Iza, E.
    Martinez, M.
    Lopez-Vivanco, G.
    Fernandez, R.
    Ruiz De Lobera, A.
    Rubio, I.
    Casas, R.
    Mane, J. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 235 - 235
  • [45] Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma
    Meyer, F
    Lueck, A
    Hribaschek, A
    Lippert, H
    Ridwelski, K
    CHEMOTHERAPY, 2004, 50 (06) : 289 - 296
  • [46] A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the cancer and leukaemia Group B 90102
    Philips, George K.
    Halabi, Susan
    Sanford, Ben L.
    Bajorin, Dean
    Small, Eric J.
    BJU INTERNATIONAL, 2008, 101 (01) : 20 - 25
  • [47] Phase I of fixed-dose-rate gemcitabine in combination with bortezomib in patients with advanced solid tumors
    Luu, T. H.
    Chow, W. A.
    Lim, D.
    Koczywas, M.
    Frankle, P.
    Cristea, M.
    Somlo, G.
    Morgan, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma
    Tempero, M
    Plunkett, W
    van Haperen, VR
    Hainsworth, J
    Hochster, H
    Lenzi, R
    Abbruzzese, J
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) : 3402 - 3408
  • [49] A phase I study, with expanded cohort, of biweekly fixed-dose rate gemcitabine (FDR GEM) plus capecitabine (CAP) in patients with advanced pancreatic (APC) and biliary carcinomas (ABC)
    Espinoza, A. M.
    Ko, A. H.
    Venook, A. P.
    Bergsland, E. K.
    Jones, K. A.
    Kelley, R. K.
    Korn, W. M.
    Dito, E.
    Ong, A.
    Tempero, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Morizane, Chigusa
    Okusaka, Takuji
    Ueno, Hideki
    Kondo, Shunsuke
    Ikeda, Masafumi
    Furuse, Junji
    Shinichi, Ohkawa
    Nakachi, Kohei
    Mitsunaga, Shuichi
    Kojima, Yasushi
    Suzuki, Eiichiro
    Ueno, Makoto
    Yamaguchi, Tomohiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 957 - 964
12345